vs
Side-by-side financial comparison of NEXPOINT DIVERSIFIED REAL ESTATE TRUST (NXDT) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
NEXPOINT DIVERSIFIED REAL ESTATE TRUST is the larger business by last-quarter revenue ($18.4M vs $12.6M, roughly 1.5× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -193.1%, a 443.8% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -29.0%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 19.9%).
NexPoint Diversified Real Estate Trust is a publicly traded US real estate investment trust. It acquires, manages and optimizes a diversified portfolio covering multifamily housing, industrial facilities, offices and neighborhood retail, generating returns via rental income and long-term property value appreciation.
NXDT vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.4M | $12.6M |
| Net Profit | $-35.5M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | -18.8% | — |
| Net Margin | -193.1% | 250.7% |
| Revenue YoY | -29.0% | 24080.8% |
| Net Profit YoY | -291.1% | 250.9% |
| EPS (diluted) | $-0.73 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.4M | $12.6M | ||
| Q3 25 | $17.5M | $0 | ||
| Q2 25 | $21.0M | $0 | ||
| Q1 25 | $29.1M | $12.0K | ||
| Q4 24 | $25.9M | $52.0K | ||
| Q3 24 | $22.2M | $65.0K | ||
| Q2 24 | $22.3M | $114.0K | ||
| Q1 24 | $12.8M | $140.0K |
| Q4 25 | $-35.5M | $31.5M | ||
| Q3 25 | $-13.7M | $-7.4M | ||
| Q2 25 | $-45.3M | $-1.7M | ||
| Q1 25 | $-34.3M | $-13.9M | ||
| Q4 24 | $-9.1M | — | ||
| Q3 24 | $-10.0M | $-17.1M | ||
| Q2 24 | $-9.8M | $-17.9M | ||
| Q1 24 | $-22.7M | $-12.7M |
| Q4 25 | -18.8% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | -0.6% | — | ||
| Q1 25 | 19.0% | -122758.3% | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | -26.8% | -28604.6% | ||
| Q2 24 | 2.7% | -16720.2% | ||
| Q1 24 | 2.1% | -9987.1% |
| Q4 25 | -193.1% | 250.7% | ||
| Q3 25 | -78.4% | — | ||
| Q2 25 | -215.1% | — | ||
| Q1 25 | -118.0% | -115550.0% | ||
| Q4 24 | -35.0% | — | ||
| Q3 24 | -45.2% | -26380.0% | ||
| Q2 24 | -43.9% | -15668.4% | ||
| Q1 24 | -177.3% | -9049.3% |
| Q4 25 | $-0.73 | $0.56 | ||
| Q3 25 | $-0.29 | $-0.13 | ||
| Q2 25 | $-0.99 | $-0.03 | ||
| Q1 25 | $-0.80 | $-0.25 | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.25 | $-0.32 | ||
| Q2 24 | $-0.24 | $-0.33 | ||
| Q1 24 | $-0.59 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $700.1M | $59.0M |
| Total Assets | $1.1B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $40.3M | ||
| Q3 25 | $5.3M | $48.6M | ||
| Q2 25 | $4.7M | $31.2M | ||
| Q1 25 | $9.5M | $48.9M | ||
| Q4 24 | $8.8M | $52.9M | ||
| Q3 24 | $8.5M | $76.3M | ||
| Q2 24 | $28.4M | $63.5M | ||
| Q1 24 | $20.2M | $82.3M |
| Q4 25 | $700.1M | $59.0M | ||
| Q3 25 | $739.0M | $26.5M | ||
| Q2 25 | $752.7M | $32.8M | ||
| Q1 25 | $802.7M | $33.8M | ||
| Q4 24 | $836.5M | $46.1M | ||
| Q3 24 | $842.9M | $65.5M | ||
| Q2 24 | $859.1M | $80.5M | ||
| Q1 24 | $863.0M | $96.2M |
| Q4 25 | $1.1B | $68.9M | ||
| Q3 25 | $1.1B | $54.2M | ||
| Q2 25 | $1.1B | $62.1M | ||
| Q1 25 | $1.2B | $77.7M | ||
| Q4 24 | $1.2B | $110.5M | ||
| Q3 24 | $1.2B | $135.2M | ||
| Q2 24 | $1.2B | $149.9M | ||
| Q1 24 | $1.1B | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-8.4M | ||
| Q3 25 | $835.0K | $17.4M | ||
| Q2 25 | $75.0K | $-17.7M | ||
| Q1 25 | $7.1M | $-4.0M | ||
| Q4 24 | $-11.7M | $-23.4M | ||
| Q3 24 | $497.0K | $12.8M | ||
| Q2 24 | $-5.5M | $-18.7M | ||
| Q1 24 | $-2.6M | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
